Anti-SN-38 Mouse mAb产品货号 产品规格 目录价 数量 31905ES60 100 μg 3885.00 加入购物车 31905ES80 1 mg 23885.00 加入购物车批量采购, 请点击询价下载产品说明书 产品说明书 FAQ COA 已发表文献 产品简介SN38 is the active metabolite of the chemotherapy drug irinotecan (Camptosar). It is a ...
The present invention relates to an anti adp-2 antibody or a therapeutic ADC comprising SN-38, which is bound to an antigen binding antibody fragment, and more specifically to a lactozigzgovectanner.The ADC is administered to an object with resistance to pretreatment using a checkpoint inhibitor...
Sacituzumabgovitecan (IMMU-132) is an antibody–drug conjugate(ADC) made from a humanized anti-Trop-2 monoclonal antibody (hRS7)conjugated with the active metabolite of irinotecan, SN-38. In additionto its further characterization, as the clinical utility of IMMU-132expands to an ever-widening...
为助力ADC的药代动力学分析,合佑生生物推出多款Anti-payload抗体,Hycells Anti-Payload 抗体具有高特异性、高稳定性、高灵敏度的特质,可用于ADC药物的血浆/血清动力学分析、药物结合亲和力的测定、DAR值分析以及ADC药物的疗效评估等加速ADC药物研发进程,为其临...
Entertainment venues, office buildings, restaurants, and public transportation waiting areas are the places with the highest incidence of violation of the city's anti-smoking rule, they said. Citizens have voiced support for a ...
Introduction: SN-38 (7-Ethyl-10-hydroxycamptothecin) is a potent active metabolite of irinotecan (Camptosar, Pfizer) with a wide range of anti-tumor effects for pancreatic, ovarian, lung, and breast cancer models as well as for colorectal cancer. However, it has extremely low solubility in ...
The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan.
The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior ...
The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior ...
The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior ...